Ozmosi | Bexarotene Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

Bexarotene

Alternative Names: bexarotene, targretin, lgd1069
Clinical Status: Inactive
Latest Update: 2026-06-04
Latest Update Note: Clinical Trial Update

Product Description

Bexarotene is used to treat cutaneous T-cell lymphoma (CTCL, a type of skin cancer) in people whose disease could not be treated successfully with at least one other medication. Bexarotene is in a class of medications called retinoids. It works by stopping the growth of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a608006.html)

Mechanisms of Action: RXR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Argentina | Austria | Belgium | Brazil | Chile | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Peru | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Turkey | United Kingdom | United States | Venezuela

Approved Indications: None

Company: Eisai
Company Location:
Company Founding Year: 1941
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bexarotene

Countries in Clinic: Japan

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: T-Cell Leukemia|T-Cell Lymphoma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

JapicCTI-194908

JapicCTI-194908

P2

Active

T-Cell Lymphoma|T-Cell Leukemia

2023-12-31